Nile Therapeutics, Inc. – Bull of the Day

Nile Therapeutics, Inc. (NLTX) is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF). Prior phase I and phase II data so far has been highly encouraging. With a market capitalization of only $14 million, Nile Therapeutics shares are bafflingly under-valued.

We believe with positive data from the ongoing phase II program in hand the company is worth at least $80 to 100 million. Taking the mid-range at $90 million, and then backing out the $20 million most likely required to fund the phase IIb program, we arrive at a value of $70 million for Nile Therapeutics. This equates to a price of $2.00 per share.
 
Zacks Investment Research

Comments

• Enhanced Categores

  • Analyst Opinions (34434)
  • ETF Picks (170)
  • Mergers and Acquisitions (3686)
  • Stock Picks (1589)
  • Stocks to Sell (710)
  • Uncategorized (61)

• Archives

  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008

• Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

• Pages

  • About Us
  • Contact Us

• 
  

• About

  StockPickBloggers.com brings you the hottest stock picks from the investment community.

• Blogroll

  • Bear of the Day - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.
  • Bull of the Day - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.
  • Hot Stock Picks - Hot stock picks from the stock market neural network scan of Stocknod.com. Get today’s best stock picks from the leader in stock picks analysis.
  • Investools
  • MarketRiders Blog - How To Become A Better Investor
  • Marketwire – Mergers and Acquisitions - Marketwire – Mergers and Acquisitions
  • Motley Fool
  • Seeking Alpha
  • The Stock Advisors - Explore the world of financial newsletters.  For years, independent newsletter advisors have provided their subscribers with better returns than most other sources.  Most of the greatest stock pickers in the world allow us to reprint stock recom
  • The StockCharts.com Market Message - Get exclusive commentary on what’s going on in the market at Stockcharts.com. The Market Message is a paid service, for information regarding signing up please visit http://stockcharts.com.
  • US Economy & Stock Market Analysis with Stock Picks & Free Investing Tips - Stay Connected – Never miss trade
  • Zack's Analyst Opinions - Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners.